Details for Patent: 10,500,208

Which drugs does patent 10,500,208 protect, and when does it expire?

Patent 10,500,208 protects APONVIE and CINVANTI and is included in two NDAs.

This patent has nine patent family members in five countries.

Summary for Patent: 10,500,208

Title:	Emulsion formulations of aprepitant
Abstract:	Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Inventor(s):	Ottoboni; Thomas B. (Belmont, CA), Han; Han (Mountain View, CA)
Assignee:	HERON THERAPEUTICS, INC. (San Diego, CA)
Application Number:	15/398,928
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,500,208
Patent Claim Types: see list of patent claims	Formulation; Process;

Drugs Protected by US Patent 10,500,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes			Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes			Y

International Family Members for US Patent 10,500,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	106852118
European Patent Office	3193830
Japan	2017533183
Japan	2019196398
Japan	2022092040